Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing--the obvious and not so obvious.
McCarty
Marya E
ME
Department of Cancer Biology and Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Ellis
Lee M
LM
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D003510:Cyclohexanes; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000494:pharmacology / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors; D053773:Transforming Growth Factor beta1; D011503:Transglutaminases / Q000037:antagonists & inhibitors; D014945:Wound Healing / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D012717:Sesquiterpenes; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C116890:Semaxinib; D011503:Transglutaminases; D011505:Protein-Tyrosine Kinases; D000077609:O-(Chloroacetylcarbamoyl)fumagillol